Home Alzheimer’s Disease Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final...

Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final Analysis

The phase 3 TRYbeCA-1 trial (NCT03665441) evaluating Eryaspase for the second-line treatment of pancreatic cancer will continue without modification following a planned interim superiority analysis conducted by an independent data monitoring committee (IDMC), according to the therapy’s developer, Erytech Pharma.

The interim analysis was triggered when two-thirds of the total number of events had occurred and permitted the potential for halting the trial early if the primary end point of overall survival (OS) superiority reached statistical significance, adjusting the statistical threshold for the interim review. Importantly, no safety issues have been identified thus far and the company remains blinded to the primary and secondary end point data.

The randomized, controlled trial has enrolled a total of 512 patients at approximately 90 clinical sites in Europe and the United States….

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments